We are live on ! Find out more
NRIX icon

Nurix Therapeutics
NRIX

118 hedge funds and large institutions have $561M invested in Nurix Therapeutics in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 51 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

173,900% more call options, than puts

Call options by funds: $1.74M | Put options by funds: $1K

150% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 8

122% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 23

11% more funds holding

Funds holding: 106 → 118 (+12)

1% less capital invested

Capital invested by funds: $568M → $561M (-$7.2M)

8.58% less ownership

Funds ownership: 100.1% → 91.52% (-8.6%)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
118
Holders Change
+12
Holders Change %
+11.32%
% of All Funds
2.03%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
20
Increased
51
Reduced
23
Closed
8
Calls
$1.74M
Puts
$1K
Net Calls
+$1.74M
Net Calls Change
-$400K

Top Buyers

1
AIM
ARK Investment Management
Florida
+$8.04M
2
Goldman Sachs
Goldman Sachs
New York
+$7.81M
3
WA
Wasatch Advisors
Utah
+$6.24M
4
BlackRock
BlackRock
New York
+$5.82M
5
N
Nuveen
North Carolina
+$3.61M

Top Sellers

1
TGI
TRV GP III
Massachusetts
-$24.4M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$16.1M
3
EAM
Eventide Asset Management
Massachusetts
-$14.6M
4
FCMI
Foresite Capital Management IV
California
-$8.58M
5
SCM
Soleus Capital Management
Connecticut
-$7.76M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$50.6M – – –
BlackRock
2
BlackRock
New York
$48.5M +$5.82M +367,743 +11%
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$47M -$16.1M -1,014,471 -22%
RG
4
Redmile Group
California
$39.2M – – –
WA
5
Wasatch Advisors
Utah
$34.6M +$6.24M +394,374 +17%
State Street
6
State Street
Massachusetts
$30.1M +$3.09M +195,453 +9%
Vanguard Group
7
Vanguard Group
Pennsylvania
$28.2M +$781K +49,370 +2%
DTC
8
Deep Track Capital
Connecticut
$26.8M -$6.05M -382,543 -16%
BCLSI
9
Bain Capital Life Sciences Investors
Massachusetts
$23.8M – – –
Fidelity Investments
10
Fidelity Investments
Massachusetts
$22M -$1.66M -105,004 -6%
AIM
11
ARK Investment Management
Florida
$16.8M +$8.04M +507,797 +65%
BC
12
Boxer Capital
California
$16M – – –
PAMS
13
Pictet Asset Management (Switzerland)
Switzerland
$14M -$5.6M -354,016 -25%
T. Rowe Price Investment Management
14
T. Rowe Price Investment Management
Maryland
$12.9M +$15.7M +992,428 New
CS
15
Candriam SCA
Luxembourg
$10.8M -$218K -13,800 -2%
Goldman Sachs
16
Goldman Sachs
New York
$10.8M +$7.81M +493,236 +149%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$10.6M +$683K +43,168 +6%
Millennium Management
18
Millennium Management
New York
$9.64M -$1.14M -72,003 -9%
DCM
19
DAFNA Capital Management
California
$7.38M – – –
N
20
Nuveen
North Carolina
$7.2M +$3.61M +228,071 +70%
SCM
21
Soleus Capital Management
Connecticut
$6.57M -$7.76M -490,348 -49%
Morgan Stanley
22
Morgan Stanley
New York
$6.26M -$1.61M -101,563 -17%
Northern Trust
23
Northern Trust
Illinois
$5.26M +$246K +15,548 +4%
Charles Schwab
24
Charles Schwab
California
$4.88M +$1.33M +84,114 +29%
Bessemer Group
25
Bessemer Group
New Jersey
$4.66M +$827K +52,274 +17%
1
2 3 4 5

NRIX Hedge Fund Activity: Q3 2022 in Review

118 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q3 2022, worth a combined $561M — down 1.3% from $568M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new NRIX positions and 8 closed out — a net gain of 12 holders — while 51 added to existing stakes and 23 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $8.04M. The largest seller was TRV GP III, exiting entirely with an estimated $24.4M sold.

  • 118 institutional investors held Nurix Therapeutics (NRIX) as of Q3 2022, up from 106 in Q2 2022.
  • Funds reported $561M of Nurix Therapeutics stock for Q3 2022, down 1.3% quarter-over-quarter.
  • 20 funds opened new Nurix Therapeutics positions in Q3 2022 and 8 closed out, a net change of +12 holders.
  • The largest Nurix Therapeutics buyer in Q3 2022 was ARK Investment Management, an estimated $8.04M added.
  • The largest Nurix Therapeutics seller in Q3 2022 was TRV GP III, an estimated $24.4M sold.

Based on aggregated 13F filings for Q3 2022.